Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra(TM) in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Stock Information for Enlivex Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enlivex Ltd.

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
Enlivex Announces $400,000,000 Private Placement
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.